BioMed Research International / 2012 / Article / Tab 3

Research Article

Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects

Table 3

Association of tPA Alu repeat-I/D polymorphism with type 2 diabetes mellitus in Malaysian subjects.

tPA Alu repeat I/D polymorphismControl ( 𝑛 = 1 3 1 )Type 2 diabetes mellitusTotal type 2 diabetes mellitus ( 𝑛 = 3 0 3 )
Without MetS
( 𝑛 = 7 6 )
With MetS
( 𝑛 = 2 2 7 )

Risk allele frequency (Insertion)0.480.470.500.49
II/ID/DD (frequency)0.23/0.49/0.280.28/0.50/0.220.26/0.48/0.260.25/0.49/0.26
Recessive modelOdds ratio1.883.321.34
95% CI0.81–4.41.28–8.570.66–2.9
𝑃 value0.140.0130.39
Dominant modelOdds ratio1.021.211.27
95% CI0.44–2.370.51–2.90.61–2.65
𝑃 value0.960.660.52
Additive modelOdds ratio1.281.481.24
95% CI0.77–2.130.87–2.510.8–1.7
𝑃 value0.340.150.34

In the additive model, genotype of homozygote for the nonrisk allele D/D (0/0), heterozygote I/D (1/0), and homozygote for the risk allele I/I (1/1) was coded as 0, 1, and 2, respectively. The recessive model was defined as I/I versus (I/D + D/D), dominant model as (I/I + I/D) versus D/D and additive model as D/D, versus I/D versus I/I. The results presented odds ratio, 95% CI and 𝑃 -value adjusted for age, gender, race, family history of diabetes and BMI as covariates which evaluated by hierarchical logistic regression. MetS: metabolic syndrome.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.